Clinical Trial Update: Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Smoflipid 20% to Intralipid 20% in hospitalized neonates and infants requiring parenteral nutrition; study terminated with posted result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hospitalized Neonates and Infants Requiring Parenteral Nutrition

Drugs mentioned

• Intralipid 20% (intravenous lipid emulsion 20%)
• SMOFlipid 20%

Snippet

Sponsor: Fresenius Kabi | Conditions: Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 Days | Phase 3 | Status: TERMINATED | Results posted: 2022-01-05